Literature DB >> 7683654

Differences in the properties and enzymatic specificities of the two active sites of angiotensin I-converting enzyme (kininase II). Studies with bradykinin and other natural peptides.

E Jaspard1, L Wei, F Alhenc-Gelas.   

Abstract

Angiotensin I-converting enzyme (ACE, E.C.3.4.15.1) has been recently shown to contain two very similar domains, each of which bears a functional active site hydrolyzing Hip-His-Leu or angiotensin I (AI). The substrate specificity of the two active sites of ACE was compared using wild-type recombinant ACE and mutants, where one active site is suppressed by deletion or inactivated by mutations of 2 histidines coordinating an essential zinc atom. Both active sites converted bradykinin (BK) to BK1-7 and BK1-5 with similar kinetics and with Kappm at least 30 times lower and kcat/kappm 10 times higher than for AI. The carboxyl-terminal active site, but not the amino-terminal site, was activated by chloride; however, chloride activation was minimal compared with AI. Both domains also hydrolyzed substance P and cleaved a carboxyl-terminal protected dipeptide and tripeptide. The carboxyl-terminal active site was more readily activated by chloride and hydrolyzed substance P faster. Luteinizing-hormone releasing hormone was hydrolyzed by both active sites, but hydrolysis by the amino-terminal active site was faster. It performed the endoproteolytic amino-terminal cleavage of this peptide at least 30 times faster than the carboxyl-terminal active site. Both active sites cleaved a carboxyl-terminal tripeptide from luteinizing hormone-releasing hormone. Thus, both active sites of ACE possess dipeptidyl carboxypeptidase and endopeptidase activities. However, only the carboxyl-terminal active site can undergo a chloride-induced alteration that greatly enhances the hydrolysis of AI or substance P, and the amino-terminal active site possesses an unusual amino-terminal endoproteolytic specificity for a natural peptide. This suggests physiologically important differences between the subsites of the two active centers, and different substrate specificity, despite the high degree of sequence homology.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7683654

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  63 in total

Review 1.  Newly recognized physiologic and pathophysiologic actions of the angiotensin-converting enzyme.

Authors:  Sebastien Fuchs; Kristen Frenzel; Hong D Xiao; Jonathan W Adams; Hui Zhao; George Keshelava; Lu Teng; Kenneth E Bernstein
Journal:  Curr Hypertens Rep       Date:  2004-04       Impact factor: 5.369

Review 2.  Angiotensin I-converting enzyme inhibitors are allosteric enhancers of kinin B1 and B2 receptor function.

Authors:  Ervin G Erdös; Fulong Tan; Randal A Skidgel
Journal:  Hypertension       Date:  2010-01-11       Impact factor: 10.190

3.  Validated ligand mapping of ACE active site.

Authors:  Daniel J Kuster; Garland R Marshall
Journal:  J Comput Aided Mol Des       Date:  2005-11-24       Impact factor: 3.686

Review 4.  Interacting cogs in the machinery of the renin angiotensin system.

Authors:  Lizelle Lubbe; Edward D Sturrock
Journal:  Biophys Rev       Date:  2019-06-08

5.  A novel peptide-processing activity of insect peptidyl-dipeptidase A (angiotensin I-converting enzyme): the hydrolysis of lysyl-arginine and arginyl-arginine from the C-terminus of an insect prohormone peptide.

Authors:  R Isaac; L Schoofs; T A Williams; D Veelaert; M Sajid; P Corvol; D Coates
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

6.  In vivo bradykinin B2 receptor activation reduces renal fibrosis.

Authors:  Joost P Schanstra; Eric Neau; Pascale Drogoz; Miguel A Arevalo Gomez; José Miguel Lopez Novoa; Denis Calise; Christiane Pecher; Michael Bader; Jean-Pierre Girolami; Jean-Loup Bascands
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

7.  Human ACE and bradykinin B2 receptors form a complex at the plasma membrane.

Authors:  Zhenlong Chen; Peter A Deddish; Richard D Minshall; Robert P Becker; Ervin G Erdös; Fulong Tan
Journal:  FASEB J       Date:  2006-11       Impact factor: 5.191

Review 8.  A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme.

Authors:  Kenneth E Bernstein; Frank S Ong; Wendell-Lamar B Blackwell; Kandarp H Shah; Jorge F Giani; Romer A Gonzalez-Villalobos; Xiao Z Shen; Sebastien Fuchs; Rhian M Touyz
Journal:  Pharmacol Rev       Date:  2012-12-20       Impact factor: 25.468

9.  Angiotensin I-converting enzyme Gln1069Arg mutation impairs trafficking to the cell surface resulting in selective denaturation of the C-domain.

Authors:  Sergei M Danilov; Sergey Kalinin; Zhenlong Chen; Elena I Vinokour; Andrew B Nesterovitch; David E Schwartz; Olivier Gribouval; Marie-Claire Gubler; Richard D Minshall
Journal:  PLoS One       Date:  2010-05-03       Impact factor: 3.240

10.  The N domain of human angiotensin-I-converting enzyme: the role of N-glycosylation and the crystal structure in complex with an N domain-specific phosphinic inhibitor, RXP407.

Authors:  Colin S Anthony; Hazel R Corradi; Sylva L U Schwager; Pierre Redelinghuys; Dimitris Georgiadis; Vincent Dive; K Ravi Acharya; Edward D Sturrock
Journal:  J Biol Chem       Date:  2010-09-08       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.